OMN-6
- Generic Name
- OMN-6
Paratek to Present Groundbreaking Clinical Data on NUZYRA for NTM and CABP at ATS 2025
• Paratek Pharmaceuticals will present results from two significant clinical studies of NUZYRA (omadacycline) at the ATS 2025 International Conference, including the first-ever placebo-controlled trial in Mycobacterium abscessus complex pulmonary disease.
• The Phase 2b study in nontuberculous mycobacterial pulmonary disease (NTM PD) addresses a significant unmet need, while the Phase 3 OPTIC-2 study confirms NUZYRA's efficacy and safety profile in community-acquired bacterial pneumonia.
• NUZYRA, a next-generation tetracycline designed to overcome resistance, has established the largest clinical trial dataset in pneumonia across all antibiotics approved by the FDA in the last decade.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath